Compounds > levofloxacin

Page last updated: 2024-09-04

levofloxacin and ziprasidone

levofloxacin has been researched along with ziprasidone in 8 studies

Compound Research Comparison

Studies (levofloxacin)	Trials (levofloxacin)	Recent Studies (post-2010) (levofloxacin)	Studies (ziprasidone)	Trials (ziprasidone)	Recent Studies (post-2010) (ziprasidone)
4,346	581	2,209	1,068	254	362

Protein Interaction Comparison

Protein	Taxonomy	levofloxacin (IC50)	ziprasidone (IC50)
D(2) dopamine receptor	Homo sapiens (human)		0.005
Aspartate aminotransferase, cytoplasmic	Homo sapiens (human)		5.39
D	Rattus norvegicus (Norway rat)		0.1514
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)		0.1514
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)		0.1514
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)		0.1514
Sodium-dependent dopamine transporter	Rattus norvegicus (Norway rat)		0.1514
Alpha-1D adrenergic receptor	Homo sapiens (human)		0.011
5-hydroxytryptamine receptor 2A	Homo sapiens (human)		0.0004
Alpha-1A adrenergic receptor	Homo sapiens (human)		0.011
Alpha-1B adrenergic receptor	Homo sapiens (human)		0.011
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)		0.2301

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (75.00)	29.6817
2010's	2 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Nagashima, R; Nishikawa, T; Tobita, M	1
Andricopulo, AD; Moda, TL; Montanari, CA	1
Lombardo, F; Obach, RS; Waters, NJ	1
Jia, L; Sun, H	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1

Reviews

1 review(s) available for levofloxacin and ziprasidone

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

7 other study(ies) available for levofloxacin and ziprasidone

Article	Year
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11 Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated	2005
Hologram QSAR model for the prediction of human oral bioavailability. Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24 Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship	2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Support vector machines classification of hERG liabilities based on atom types. Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11 Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010